Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 17Fallopian Tube Neoplasms 17Glioblastoma 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 6Carcinoma, Renal Cell 6Brenner Tumor 6Melanoma 5Uterine Cervical Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Gliosarcoma 4Breast Neoplasms 4Brain Neoplasms 4Triple Negative Breast Neoplasms 3Recurrent Squamous Cell Lung Carcinoma 3Oligodendroglioma 3Neoplasm Metastasis 3Lymphoma, Large B-Cell, Diffuse 3Colonic Neoplasms 3Uveal Melanoma 2Spinal Cord Neoplasms 2Rectal Neoplasms 2Prostatic Neoplasms 2Medulloblastoma 2Glioma 2Endometrial Adenocarcinoma 2Carcinoma 2Astrocytoma 2Adenocarcinoma of Lung 2

Interventions

olaparib 1cediranib 1bomedemstat 1atezolizumab 1Platinum 1Immunoglobulin G 1Etoposide 1Disulfides 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Extensive Stage Lung Small Cell Carcinoma × Disulfides × Clear all
NCT05191797 2024-09-26

Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer

University of Washington

Phase 1/2 Terminated
3 enrolled 8 charts

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡